These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. John T, Liu G, Tsao MS. Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292 [Abstract] [Full Text] [Related]
9. Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer--a review of the literature. Araújo A, Ribeiro R, Azevedo I, Coelho A, Soares M, Sousa B, Pinto D, Lopes C, Medeiros R, Scagliotti GV. Oncologist; 2007 Feb; 12(2):201-10. PubMed ID: 17296816 [Abstract] [Full Text] [Related]
11. What phase III trials are needed to improve the treatment of advanced non-small-cell lung cancer? Saijo N. Nat Clin Pract Oncol; 2005 Jun; 2(6):275. PubMed ID: 16264964 [No Abstract] [Full Text] [Related]
12. Targeted therapy for nonsmall cell lung cancer: focusing on angiogenesis, the epidermal growth factor receptor and multikinase inhibitors. Kotteas EA, Charpidou AG, Syrigos KN. Anticancer Drugs; 2010 Feb; 21(2):151-68. PubMed ID: 20016368 [Abstract] [Full Text] [Related]
13. Multitargeted inhibitors in lung cancer: new clinical data. Bar J, Herbst RS, Onn A. Clin Lung Cancer; 2008 Feb; 9 Suppl 3():S92-9. PubMed ID: 19419930 [Abstract] [Full Text] [Related]